Clinical Trials
34 trialsCOARC
University of Texas Southwestern Medical Center
VS-UrineID
University of Kansas Medical Center
ISABELLA
University of Aberdeen
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
Brown University
A Novel Application of 2% Lidocaine Injection for Male Rigid cycstoscopy-a Patient-blinded Randomised Trial
Second Xiangya Hospital of Central South University
ARTGU
University Health Network, Toronto
Longitudinal Geriatric Assessment to Optimize Outcomes of Older Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy
University of Kansas Medical Center
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
QuantumLeap Healthcare Collaborative
Rideau
University of British Columbia
sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer
University of Southern California
Low-moderate Intensity Pedaling During Immunotherapy Administration
Rush University Medical Center
(BLASST)-3
Dana-Farber Cancer Institute
Continuous Bladder Irrigation Following Transurethral Resection of Bladder Tumors
Case Comprehensive Cancer Center
Mapping 3D Bladder
University Health Network, Toronto
Relationship Between Circulating Tumor Cell Cultures' Treatment Response and Clinical Outcomes
UNC Lineberger Comprehensive Cancer Center
TRIO Bladder
Duke University
Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention
H. Lee Moffitt Cancer Center and Research Institute
Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression
Dana-Farber Cancer Institute
Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer
University of Wisconsin, Madison
Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer
The University of Texas Health Science Center at San Antonio
A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies
Stanford University
Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer
University of Southern California
Improving Sensitivity of Urine Cytology for Bladder Cancer
Johns Hopkins University
Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer
University of California, San Francisco
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
Washington University School of Medicine
Urinary Diversion During Robotic Assisted Radical Cystectomy in Patients With Bladder Cancer
Case Comprehensive Cancer Center
Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
Alliance for Clinical Trials in Oncology
Imaging During Surgery in Diagnosing Patients With Prostate, Bladder, or Kidney Cancer
Stanford University
Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma
University of Colorado, Denver
Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer
University of Southern California
Gemcitabine in Treating Patients With Recurrent or Refractory Bladder Cancer
University of Pittsburgh
Celecoxib and Rosiglitazone in Treating Patients Who Are Undergoing Cystoscopic Surveillance for Early-Stage Noninvasive Carcinoma of the Bladder or Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder
Fox Chase Cancer Center
Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer
University of Michigan Rogel Cancer Center
Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel
M.D. Anderson Cancer Center